EE200200595A - Hemostaatiliselt aktiivne vWF sisaldav ravimpreparaat ja meetod selle valmistamiseks - Google Patents

Hemostaatiliselt aktiivne vWF sisaldav ravimpreparaat ja meetod selle valmistamiseks

Info

Publication number
EE200200595A
EE200200595A EEP200200595A EEP200200595A EE200200595A EE 200200595 A EE200200595 A EE 200200595A EE P200200595 A EEP200200595 A EE P200200595A EE P200200595 A EEP200200595 A EE P200200595A EE 200200595 A EE200200595 A EE 200200595A
Authority
EE
Estonia
Prior art keywords
vwf
fraction
preparation
active
pharmaceutical composition
Prior art date
Application number
EEP200200595A
Other languages
English (en)
Estonian (et)
Inventor
Josic Djuro
Stadler Monika
Gruber Gerhard
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of EE200200595A publication Critical patent/EE200200595A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200200595A 2000-04-18 2001-04-04 Hemostaatiliselt aktiivne vWF sisaldav ravimpreparaat ja meetod selle valmistamiseks EE200200595A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108430A EP1148063A1 (de) 2000-04-18 2000-04-18 Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
PCT/EP2001/003819 WO2001079260A1 (de) 2000-04-18 2001-04-04 Haemostatisch aktives vwf enthaltendes präparat und verfahren zu seiner herstellung

Publications (1)

Publication Number Publication Date
EE200200595A true EE200200595A (et) 2004-04-15

Family

ID=8168496

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200595A EE200200595A (et) 2000-04-18 2001-04-04 Hemostaatiliselt aktiivne vWF sisaldav ravimpreparaat ja meetod selle valmistamiseks

Country Status (24)

Country Link
US (2) US7166709B2 (es)
EP (2) EP1148063A1 (es)
JP (1) JP4976634B2 (es)
KR (1) KR100685448B1 (es)
CN (1) CN100448888C (es)
AT (1) ATE306494T1 (es)
AU (2) AU2001263835B2 (es)
BR (1) BR0110193A (es)
CA (1) CA2406626C (es)
CZ (1) CZ303932B6 (es)
DE (1) DE50107689D1 (es)
DK (1) DK1274721T3 (es)
EA (1) EA006209B1 (es)
EE (1) EE200200595A (es)
ES (1) ES2247117T3 (es)
HU (1) HU225992B1 (es)
IL (2) IL152173A0 (es)
MX (1) MXPA02010017A (es)
NO (1) NO324773B1 (es)
RS (1) RS50835B (es)
SI (1) SI1274721T1 (es)
UA (1) UA76714C2 (es)
WO (1) WO2001079260A1 (es)
ZA (1) ZA200208396B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
AU2011260258B2 (en) * 2010-06-01 2015-07-09 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
EP2619225B1 (en) 2010-09-20 2016-06-15 Octapharma AG Process for production of fibrinogen
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
US10112972B2 (en) 2012-03-13 2018-10-30 Octapharma Ag Process for production of fibrinogen and fibrinogen produced thereby
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
CN116284337A (zh) * 2023-03-30 2023-06-23 同路生物制药有限公司 以冷沉淀peg沉淀及色谱层析法制备血友病因子的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
EP0367840B1 (de) 1988-11-05 1993-02-03 Octapharma AG Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
DK1274721T3 (da) 2006-02-13
HUP0301211A2 (hu) 2003-07-28
DE50107689D1 (de) 2006-02-23
CN100448888C (zh) 2009-01-07
NO324773B1 (no) 2007-12-10
ZA200208396B (en) 2004-04-30
MXPA02010017A (es) 2003-04-25
AU6383501A (en) 2001-10-30
EP1274721A1 (de) 2003-01-15
NO20025007L (no) 2002-11-28
KR20030019352A (ko) 2003-03-06
EA200201104A1 (ru) 2003-04-24
BR0110193A (pt) 2003-02-11
EP1148063A1 (de) 2001-10-24
US20070232791A1 (en) 2007-10-04
CA2406626A1 (en) 2001-10-25
ES2247117T3 (es) 2006-03-01
IL152173A0 (en) 2003-05-29
AU2001263835B2 (en) 2005-06-09
CA2406626C (en) 2012-02-21
KR100685448B1 (ko) 2007-02-23
PL358388A1 (en) 2004-08-09
EA006209B1 (ru) 2005-10-27
WO2001079260A1 (de) 2001-10-25
RS50835B (sr) 2010-08-31
HU225992B1 (en) 2008-02-28
IL152173A (en) 2007-07-24
JP2004516231A (ja) 2004-06-03
CZ20023454A3 (cs) 2003-05-14
UA76714C2 (uk) 2006-09-15
US20030138913A1 (en) 2003-07-24
US7985846B2 (en) 2011-07-26
ATE306494T1 (de) 2005-10-15
EP1274721B1 (de) 2005-10-12
US7166709B2 (en) 2007-01-23
JP4976634B2 (ja) 2012-07-18
CZ303932B6 (cs) 2013-07-03
YU78402A (sh) 2006-08-17
HUP0301211A3 (en) 2005-12-28
SI1274721T1 (sl) 2006-04-30
CN1425024A (zh) 2003-06-18
NO20025007D0 (no) 2002-10-17

Similar Documents

Publication Publication Date Title
NO20025007L (no) Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmÕte for fremstilling derav
UA11061A (uk) Спосіб розділеhhя білків крові
CA2248960A1 (en) Stable factor viii/vwf-complex
AU5465498A (en) Analysis and separation of platelet-derived growth factor proteins
CA2282843C (en) Purification of von willebrand factor by cation exchange chromatography
DK0576294T3 (da) Chondroitinase, fremgangsmåde til fremstilling af chondroitinase og farmaceutisk præparat indeholdende chondroitinase
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
BR9004626A (pt) Processo para preparar um concentrado estavel de complexo de fator viii-fator de von willebrand,concentrado de complexo de fator viii-fator de von willebrand e concentrados de proteina derivados de plasma
BR9814224A (pt) Composto, e, processo para produzir o mesmo.
ATE277073T1 (de) Verfahren und vorrichtung zur herstellung von gereinigten plasmaproteinen
DK0567448T4 (da) Fremgangsmåde til fremstilling af faktor VIII
JP2579217B2 (ja) 凝固因子▲ｉｉ▼、▲ｖｉｉ▼、▲ｉｘ▼およびｘの１または２以上を濃縮する方法
FI921101A7 (fi) Kannatettu, mekaanisesti stabiili kaksinapainen kalvo elektrodialyysissa
DK316984D0 (da) Fremgangsmaade til oploesning af peptider
ATE214618T1 (de) Desinfektion durch partikelgebundene und insolubilisierte detergentien
ATE113062T1 (de) Throminbindende substanz und verfahren zu ihrer herstellung.
Bowen et al. Electrophoresis of locust haemolymph
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
Barington et al. A Very‐High‐Purity von Willebrand Factor Preparation Containing High‐Molecular‐Weight Multimers
DE69637278D1 (de) Methode zur herstellung von thrombin
KR960023054A (ko) 재조합 인간 에리스로포이에틴의 정제 방법
KR920005994A (ko) 전체혈장으로 혈액응고 viii 인자-반 빌레브란트 인자 복합 농축물을 제조하는 방법
ES8500059A1 (es) Procedimiento para la produccion de concentrado de factor antihemofilico.
RU94028220A (ru) Способ получения целлюлозного перевязочного материала, обладающего антибактериальной и регенеративной активностью
RU94025626A (ru) Способ выделения с5 компонента комплемента человека